Jim Simons Jounce Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.9 - $1.85 $273,963 - $563,147	304,404 Added 109.93%	581,300 $1.08 Million
Q4 2022 Feb 13, 2023	BUY	$0.64 - $1.99 $126,205 - $392,420	197,196 Added 247.42%	276,896 $307,000
Q3 2022 Nov 14, 2022	SELL	$2.73 - $4.92 $358,670 - $646,394	-131,381 Reduced 62.24%	79,700 $186,000
Q2 2022 Aug 12, 2022	BUY	$2.8 - $7.67 $540,346 - $1.48 Million	192,981 Added 1066.19%	211,081 $640,000
Q1 2022 May 13, 2022	BUY	$6.01 - $8.54 $108,781 - $154,573	18,100 New	18,100 $123,000
Q3 2021 Nov 12, 2021	SELL	$5.04 - $8.73 $671,832 - $1.16 Million	-133,300 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$6.58 - $10.66 $750,054 - $1.22 Million	113,990 Added 590.32%	133,300 $906,000
Q1 2021 May 13, 2021	SELL	$6.73 - $13.87 $748,402 - $1.54 Million	-111,204 Reduced 85.2%	19,310 $198,000
Q4 2020 Feb 10, 2021	SELL	$6.37 - $10.33 $1.08 Million - $1.75 Million	-169,600 Reduced 56.51%	130,514 $914,000
Q3 2020 Nov 13, 2020	SELL	$4.58 - $10.95 $899,970 - $2.15 Million	-196,500 Reduced 39.57%	300,114 $2.45 Million
Q2 2020 Aug 13, 2020	SELL	$4.17 - $7.58 $848,595 - $1.54 Million	-203,500 Reduced 29.07%	496,614 $3.43 Million
Q1 2020 May 14, 2020	BUY	$2.91 - $8.7 $844,482 - $2.52 Million	290,200 Added 70.8%	700,114 $3.33 Million
Q4 2019 Feb 13, 2020	BUY	$2.81 - $9.21 $1.01 Million - $3.32 Million	361,006 Added 738.13%	409,914 $3.58 Million
Q3 2019 Nov 13, 2019	BUY	$3.33 - $4.93 $124,235 - $183,928	37,308 Added 321.62%	48,908 $163,000
Q2 2019 Aug 12, 2019	SELL	$4.3 - $6.73 $5,160 - $8,076	-1,200 Reduced 9.38%	11,600 $57,000
Q1 2019 May 14, 2019	SELL	$3.43 - $6.87 $683,256 - $1.37 Million	-199,200 Reduced 93.96%	12,800 $79,000
Q4 2018 Feb 13, 2019	BUY	$2.69 - $6.71 $570,280 - $1.42 Million	212,000 New	212,000 $714,000

Others Institutions Holding JNCE

# of Institutions

Shares Held

720K

Call Options Held

Put Options Held

View Full List

About Jounce Therapeutics, Inc.

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

More about JNCE

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account